Virogenbio is a global biotechnology company focused on the development of innovative medicines for immunotherapies addressing unmet needs across a range of therapeutic areas.

Holding worldwide development and commercialization rights, the company leads global clinical development and alliance management from its U.S. operations, with plans to expand its presence to the European Union.